Abstract: The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

Abstract: A compound of formula 1 wherein: R1 is C1-C4-alkyl; R2 is C1-C4-alkyl; and R3 is C1-C4-alkyl or phenyl, each optionally mono- or polysubstituted, or R2 and R3 together are —CH2—CH2— or —CH2—CH2—CH2—, or the corresponding acid addition salt with a pharmacologically acceptable acid, processes for preparing such compounds, pharmaceutical compositions containing such compounds, and their use in the treatment of inflammatory and obstructive respiratory diseases.

Abstract: The present invention relates to the use of the compounds of general formula 1 wherein the groups R1, X and Y may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition for the treatment of COPD (chronic obstructive pulmonary disease), as well as new compounds of general formula 1 and processes for preparing them.

Abstract: The present invention relates to compounds of formula 1 wherein the groups X, Ra, Rb, R1, R1?, R2, R2?, R2?, R2??, V and n may have the meanings given in the claims and in the specification, and the use thereof as pharmaceutical compositions, particularly for the treatment of inflammatory and obstructive respiratory complaints.

Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R2 is hydrogen, C1-C4-alkyl, halogen, OH, or —O—C1-C4-alkyl; R3 is hydrogen, C1-C4-alkyl, OH, halogen, —O—C1-C4-alkyl, —O—C1-C4-alkylene-COOH, or —O—C1-C4-alkylene-CO—O—C1-C4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).

Abstract: A compound of formula 1 wherein: R1 is C1-C4-alkyl; R2 is C1-C4-alkyl; and R3 is C1-C4-alkyl or phenyl, each optionally mono- or polysubstituted, or R2 and R3 together are —CH2—CH2— or —CH2—CH2—CH2—, or the corresponding acid addition salt with a pharmacologically acceptable acid, processes for preparing such compounds, pharmaceutical compositions containing such compounds, and their use in the treatment of inflammatory and obstructive respiratory diseases.

Abstract: The present invention relates to the compounds of general formula 1 wherein the groups R, R1, R2, R3 and A may have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly for the treatment of inflammatory and obstructive respiratory complaints.

Abstract: A compound of formula 1 wherein the groups R1, R2, R3, R4 and n may have the meanings given in the claims and in the specification, and methods for preparing a pharmaceutical composition for the treatment of inflammatory and obstructive respiratory complaints.

Abstract: A pharmaceutical composition comprising a compound of formula 1 wherein X? is an anion with a single negative charge, and a betamimetic, optionally together with a pharmaceutically acceptable excipient, the compound of formula 1 and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of respiratory tract diseases.

Abstract: A pharmaceutical composition comprising: (a) a compound of formula 2 ?or an enantiomer, mixtures of enantiomers, racemate, physiologically acceptable acid addition salt, solvate, or hydrate thereof; and (b) a steroid, or an enantiomer, mixtures of enantiomers, racemate, pharmacologically acceptable acid addition salt, solvate, or hydrate thereof.

Abstract: A pharmaceutical composition comprising an anticholinergic and a betamimetic of formula 2 optionally together with a pharmaceutically acceptable excipient, the anticholinergic and the betamimetic optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates, processes for preparing them, and their use in the treatment of asthma, COPD, or other inflammatory or obstructive respiratory complaints.

Abstract: The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula

Abstract: A pharmaceutical composition comprising: (a) an anticholinergic of formula 1 wherein X? is an anion with a single negative charge; and (b) a compound of formula 2 or the pharmacologically acceptable acid addition salts, solvates, and hydrates thereof.

Abstract: A pharmaceutical composition comprising a compound of formula 1 1

Abstract: A compound of formula 1 1

Abstract: The present invention relates to new pharmaceutical compositions for inhalation containing one or more, preferably one, tiotropium salt combined with one or more pharmacologically acceptable acid addition salts of a compound of formula 2′, 1

Abstract: A compound of formula 1 1

Abstract: A pharmaceutical composition comprising: